Introduction: Liver cirrhosis is the final stage of progressive chronic liver diseases.This is a histopathological alteration of the liver that is characterized by the loss of the hepatic parenchyma, thus generating the formation of fibrous septa and structurally abnormal regeneration nodules, thus giving rise to a distortion of the normal hepatic architecture and an alteration of the anatomy.hepatic vasculature and microcirculation.Currently for the treatment of liver cirrhosis and its complications, there are different drugs of which the main ones are lactulose, L-ornithine, L-aspartate (LOLA) and certain antibiotics, especially rifaximin. Methodology:A bibliographic search was carried out in databases, selecting original articles, case reports and bibliographic reviews from 2009 to 2021, using the documents that will deal with Rifaximin as an alternative treatment in hepatic encephalopathy, obtaining 21 articles for the realization of this document Results: In a 2015 meta-analysis, a significant comparison was made between the use of rifaximin and some other treatments for HE, where it was shown that rifaximin has a greater reduction in plasma ammonium levels (which causes this complication).studies comparing rifaximin with placebo, other antibiotics and non-absorbable disaccharide laxatives Conclusion: IRifaximin is a dominant alternative in the treatment of acute episodes of hepatic encephalopathy and to prevent its relapses